Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00074308 · ClinicalTrials.gov registry record · Phase 1

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Melanoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT00074308 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Melanoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00074308, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Melanoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Recurrent Melanoma Stage IV Melanoma Stage III Melanoma

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG imatinib mesylate
  • OTHER pharmacological study
  • BIOLOGICAL bevacizumab

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of The University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2003-10
Est. Completion 2009-07
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00074308

The ClinicalTrials.gov registry entry for NCT00074308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (92% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00074308 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00074308 about?

NCT00074308 is a clinical study titled "Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers". Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab m...

What is the current status of trial NCT00074308?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-10. Estimated completion is 2009-07.

What conditions does trial NCT00074308 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Recurrent Melanoma, Stage IV Melanoma, Stage III Melanoma.

What interventions are being tested in trial NCT00074308?

The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), pharmacological study (OTHER), bevacizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00074308?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00074308 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Recurrent Melanoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.